Hengrui's Rosuvastatin Calcium Tablets, a Clinical First-Line Drug with Over RMB 1.7 Billion in Sales, Gains Approval and Passes Generic Evaluation

Jul 22, 2024 20:30 CST Updated 20:30

Hengrui Pharmaceutical

Chemical Drug Manufacturer

Note: This article does not constitute any investment opinions or recommendations; please refer to official/company announcements for accuracy. This article only provides an introduction to medical and health-related drugs, not a recommendation of treatment plans (if involved), and does not represent the platform's position. Authorization is required for the reprint of any article.

On July 19, according to the latest announcement on the NMPA official website,Chengdu Hengrui Pharmaceutical Co., Ltd.(Hengrui Subsidiary)Submitted Category 4 Generic DrugsRosuvastatin Calcium TabletsApproved and considered as passed. According to the PharmaCloud database,Rosuvastatin Calcium TabletsExceeding 1.7 billion yuan in sales revenue in the Chinese hospital market in 2023.

Screenshot source: NMPA official website

Rosuvastatin Calcium TabletsIt is a first-line clinical drug for lowering cholesterol and regulating blood lipids in China. WithAstraZenecaThe original research drugCrestor (Crestor)The listing has driven a burst of growth in the lipid-lowering drug market. According to the PharmaOcean database,Rosuvastatin Calcium TabletsSales in the Chinese hospital market exceeded 1.7 billion yuan in 2023.

Screenshot source:PharmCube China Hospital Sales Database

Currently,Rosuvastatin Calcium TabletsMore than 30 pharmaceutical companies in China have obtained production approval for the drug. Chongqing Yaoyou Pharmaceutical has submitted a Category 4 generic drug.Rosuvastatin Calcium TabletsThe listing applications are all under review and approval.

Screenshot source:PharmCube China Drug Evaluation Database

In 2023, cardiovascular system drugs(Chemical Drugs and Biologics)Among the top 10 best-selling products in hospitals nationwide in China,Rosuvastatin Calcium TabletsRanked 7th.

Screenshot source:PharmCube China Hospital Sales Database- Global Analysis

From 2024 to present,Hengrui(Including subsidiaries)YesThiotepa for Injection, Olmesartan Medoxomil Tablets, Rosuvastatin Calcium Tablets, Vildagliptin Tablets, Acarbose TabletsFive varieties passed the evaluation, of whichThiotepa for InjectionThe variety welcomes its first approval and secures the first generic.

END

This article is original. Please leave a message to obtain authorization for reprint.

Recent Popular Resource Acquisition

Reply to the keyword "Report", access dozens of exclusive reports produced by Yaorongyun
Reply to the keyword " in the backgroundCSCO", Obtain 2023 CSCO Guidelines
Reply to the keyword " in the backgroundASCO", Obtain 2023 ASCO Abstract by Cancer Type
Reply to the keyword " in the backgroundFirst Generic in 2023", to obtain the list of first generic drugs approved in 2023
Reply to the keyword "Medical Insurance", Obtain the 2022 Medical Insurance Catalog

Contact us to experience more professional services from PharmaCloud.

MeetingDiscussion

CombineWork

GardenDistrict

TakeWu

Database

Consultation

Customization

Service

Media

Cooperation

ClickReadRead the Original Text, apply for a free trial of PharmaCloud Enterprise Edition!